Thomas Klikovits

1.9k total citations
55 papers, 913 citations indexed

About

Thomas Klikovits is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Thomas Klikovits has authored 55 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 11 papers in Surgery. Recurrent topics in Thomas Klikovits's work include Occupational and environmental lung diseases (20 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (12 papers). Thomas Klikovits is often cited by papers focused on Occupational and environmental lung diseases (20 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (12 papers). Thomas Klikovits collaborates with scholars based in Austria, Hungary and Germany. Thomas Klikovits's co-authors include Walter Klepetko, Mir Alireza Hoda, Balázs Döme, Balázs Hegedűs, Viktória László, Bahil Ghanim, Michael Grusch, Clemens Aigner, Walter Berger and F Rényi-Vámos and has published in prestigious journals such as Cancer, Cancer Research and Annals of Surgery.

In The Last Decade

Thomas Klikovits

49 papers receiving 899 citations

Peers

Thomas Klikovits
Thomas Klikovits
Citations per year, relative to Thomas Klikovits Thomas Klikovits (= 1×) peers Jian‐Kun Hu

Countries citing papers authored by Thomas Klikovits

Since Specialization
Citations

This map shows the geographic impact of Thomas Klikovits's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Klikovits with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Klikovits more than expected).

Fields of papers citing papers by Thomas Klikovits

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Klikovits. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Klikovits. The network helps show where Thomas Klikovits may publish in the future.

Co-authorship network of co-authors of Thomas Klikovits

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Klikovits. A scholar is included among the top collaborators of Thomas Klikovits based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Klikovits. Thomas Klikovits is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Steiner, Daniel, Thomas Klikovits, Klaus Kirchbacher, et al.. (2024). Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis. Lung Cancer. 198. 107997–107997.
2.
Lang, Christian, Zsolt Megyesfalvi, Felicitas Oberndorfer, et al.. (2024). C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer. World Journal of Surgical Oncology. 22(1). 57–57. 2 indexed citations
3.
Klikovits, Thomas, Maximilian J. Hochmair, Lisa A. Schulte, et al.. (2024). Prognostic factors of recurrence and disease-free survival in radically resected pulmonary carcinoids: a real-world analysis. Journal of Thoracic Disease. 16(3). 1911–1922. 2 indexed citations
4.
Opitz, Isabelle, Olivia Lauk, Raphael S. Werner, et al.. (2024). Characteristics of Long-term Survivors With Malignant Pleural Mesothelioma. The Annals of Thoracic Surgery. 120(1). 108–116.
5.
Klikovits, Thomas, Lisa A. Schulte, Maximilian J. Hochmair, et al.. (2023). Lymph Node Log-Odds Ratio Accurately Defines Prognosis in Resectable Non-Small Cell Lung Cancer. Cancers. 15(7). 2082–2082. 3 indexed citations
6.
Kifjak, Daria, Maximilian J. Hochmair, Ruxandra‐Iulia Milos, et al.. (2023). Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists. European Journal of Radiology. 161. 110732–110732. 3 indexed citations
7.
Schelch, Karin, Thomas Mohr, Thomas Klikovits, et al.. (2023). Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis. Thoracic Cancer. 14(22). 2177–2186. 1 indexed citations
8.
Sinn, Katharina, Ariane Steindl, Karin Dieckmann, et al.. (2022). Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study. ESMO Open. 7(2). 100466–100466. 7 indexed citations
9.
Lang, Christian, Mir Alireza Hoda, Felicitas Oberndorfer, et al.. (2022). Lymphocyte-to-monocyte ratio is an independent prognostic factor in surgically treated small cell lung cancer: An international multicenter analysis. Lung Cancer. 169. 40–46. 13 indexed citations
10.
László, Viktória, Ildikó Kovács, Mir Alireza Hoda, et al.. (2018). Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo. Clinical Cancer Research. 24(15). 3729–3740. 25 indexed citations
11.
László, Viktória, Ildikó Kovács, Tamás Garay, et al.. (2018). The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Journal of Molecular Medicine. 97(2). 231–242. 34 indexed citations
12.
Marulli, Giuseppe, Erino Angelo Rendina, Walter Klepetko, et al.. (2017). Surgery for T4 lung cancer invading the thoracic aorta: Do we push the limits?. Journal of Surgical Oncology. 116(8). 1141–1149. 18 indexed citations
13.
Klikovits, Thomas, Paul Stockhammer, Viktória László, et al.. (2017). Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports. 7(1). 16456–16456. 20 indexed citations
14.
Hoda, Mir Alireza, Christine Pirker, Karin Schelch, et al.. (2016). Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. Molecular Cancer Therapeutics. 15(10). 2357–2369. 17 indexed citations
15.
Hoda, Mir Alireza, Thomas Klikovits, Karin Dieckmann, et al.. (2016). Management of malignant pleural mesothelioma—part 2: therapeutic approaches. Wiener klinische Wochenschrift. 128(17-18). 618–626. 5 indexed citations
16.
Török, Szilvia, Melinda Rezeli, Olga Kelemen, et al.. (2016). Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics. 7(2). 400–412. 54 indexed citations
17.
Hoda, Mir Ali Reza, Ryuichi Waseda, Thomas Klikovits, et al.. (2015). Trimodality Therapy Including Radical Resection for Pancoast Tumors: T4 is not a Contraindication for Radical Surgery. Annals of Oncology. 26. i24–i24.
18.
Cserepes, Mihály, Gyula Ostoros, Zoltán Lohinai, et al.. (2014). Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. European Journal of Cancer. 50(10). 1819–1828. 63 indexed citations
19.
Lauk, Olivia, Mir Alireza Hoda, Marc de Perrot, et al.. (2014). Extrapleural Pneumonectomy After Induction Chemotherapy: Perioperative Outcome in 251 Mesothelioma Patients From Three High-Volume Institutions. The Annals of Thoracic Surgery. 98(5). 1748–1754. 33 indexed citations
20.
Láng, György, Bahil Ghanim, Konrad Hötzenecker, et al.. (2014). Extracorporeal membrane oxygenation support for complex tracheo-bronchial procedures†. European Journal of Cardio-Thoracic Surgery. 47(2). 250–256. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026